Navigation Links
Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
Date:3/6/2012

SAN DIEGO, March 6, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical testing for oncology drug candidate ME-344, the Company's lead mitochondrial inhibitor.

"I am extremely proud of our clinical operations and pre-clinical research teams in reaching this important milestone, less than seven months since our IND for ME-143 was approved by the FDA to begin clinical testing," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are prepared to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors immediately following approval by the FDA."

Marshall Edwards also announced that it has commenced dosing of the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors. The Company expects to collect final safety and pharmacokinetic data from this trial by June.

"We continue to execute on the clinical development plan we set forth for our two most promising drug candidates," said Robert Mass, M.D., Chief Medical Officer of Marshall Edwards. "Now, as we await approval of our IND for ME-344 and near the completion of enrollment in our Phase I clinical trial of ME-143, we are diligently preparing for our Phase II trials."

Marshall Edwards owns exclusive worldwide rights to all of its drug candidates, including ME-143 and ME-344.

About ME-344
ME-344 is Marshall Edwards' lead mitochondrial inhibitor and an active metabolite of NV-128, a first-generation compound. Treatment of tumor cells with the Company's mitochondrial inhibitor compounds induces a rap
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
2. Marshall Edwards Announces Rights Offering to Stockholders
3. Marshall Edwards Adds $2 Million in Private Placement
4. Marshall Edwards Announces $2 Million Private Placement
5. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
6. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
7. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
8. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
9. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
10. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
11. Marshall Edwards Announces Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Investor-Edge has ... (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, ...
(Date:10/22/2014)... RPh, of Vernak Farms Pharmacy in Skaneateles, ... Roentsch Scholarship by the Professional Compounding Centers of America ... during PCCA,s International Seminar, held October 8-10, ... pharmacist and PCCA member who embodies the innovative and ... pharmacist in the compounding community. George ...
(Date:10/22/2014)... SAN FRANCISCO , Oct. 22, 2014 ... fitness and health trackers for themselves and their kids, ... Mom 2014 Report: Health & Fitness Go Mobile for ... Mom® Insights Series. BabyCenter, the number 1 pregnancy and ... which found that 55 percent of moms surveyed say ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4
... , COPENHAGEN, November 2 ... payment derived from its collaboration with,Merck & Co. Inc., ... payment was triggered following identification of several candidate,molecules that ... the original agreement. These include several accepted drug-like,characteristics and ...
... TOKYO, November 2 Sosei Group Corporation,("Sosei"; ... that Sosei Co., Ltd., its wholly owned Japanese ... ASKA Pharmaceuticals,Co., Ltd. ("ASKA", TSE First Section Index: ... SOH-075 (NorLevo(R)). , NorLevo(R) ...
Cached Medicine Technology:Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc. 2Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R)) 2
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... are only 24 hours in a day, that doesn’t seem to ... within their busy schedules for exercise and fitness. Fortunately, one does ... in shape. Here are five ways you can reach your fitness ... Your Commute , Consider riding a bike or taking the bus ... routine. If you must use your car to get to work, ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... Payers and Providers Contain Costs and ... Improve Patient Outcomes Together, HOUSTON, ... Innovent Oncology, a service division that offers a first-time,opportunity for ... specifically for the complexity of cancer,care. With a unique focus ...
... finds only 5% of Californians took benefit of nation,s 1st ... News) -- Few parents with chronically ill kids have made ... of them are not even aware it exists, according to ... adopted the nation,s first family leave law. It is funded ...
... to Contribute $5 to Support,the American Red Cross ... The Wireless Foundation,and the American Red Cross announced ... make a charitable donation to the Red Cross ... Here,s how it works:,Subscribers of participating wireless carriers ...
... Americans about the Importance of Kidney Health Remains ... Dialysis Patient,Citizens (DPC) -- a nationwide, non-profit patient ... pre-dialysis patients and family members,working to advance the ... month the addition of three new board members ...
... 2 "Move over, Madonna," read a recent,San Francisco Chronicle ... for the Soul debuted at #9 on the Billboard Pop ... Grammy Best New Artist of the,Year Amy Winehouse. This week, ... Belgium and Poland, and Double Platinum in Austria. The disc,remains ...
... two-thirds of obese adults will develop painful osteoarthritis of the ... of North Carolina at Chapel Hill suggests. , The study ... body mass index or BMI increased, with the greatest risk ... but were overweight or obese at 45 or older. , ...
Cached Medicine News:Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:Wireless Subscribers Can Text 2HELP the American Red Cross 2Health News:Wireless Subscribers Can Text 2HELP the American Red Cross 3Health News:Dialysis Patient Citizens Welcomes New Members to Board of Directors 2Health News:Dialysis Patient Citizens Welcomes New Members to Board of Directors 3Health News:Nearly half of US adults will develop painful knee osteoarthritis by age 85: study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: